Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Significance: The blood–brain barrier (BBB) prevents ingress of small molecules into the brain partly by expression of drug efflux transporters. Although several transporters are known to be involved, the role ABCG2 plays in this process is not clear. We demonstrate the ability to image ABCG2 function at the BBB by using luciferin in a luciferase-expressing mouse. This represents a direct measurement of ABCG2 function at the BBB, and demonstrates that ABCG2 does play a functional role at the BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Bioluminescence imaging of Aβ deposition in bigenic mouse models of Alzheimer's disease
Watts, J. C., Giles, K., Grillo, S. K., Lemus, A., DeArmond, S. J., & Prusiner, S. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019034108 · Cited by 109
Cited by
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
The Placental Barrier: the Gate and the Fate in Drug Distribution
Tetro, N., Moushaev, S., Rubinchik-Stern, M., & Eyal, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-017-2286-0 · Cited by 145
The Inhibitor Ko143 Is Not Specific for ABCG2
Weidner, L. D., Zoghbi, S. S., Lu, S., Shukla, S., Ambudkar, S. V., Pike, V. W., Mulder, J., Gottesman, M. M., Innis, R. B., & Hall, M. D. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225482 · Cited by 141
“For example, Ko143 was found to elevate mouse brain levels of the ABCG2 substrate D-luciferin in a bioluminescence-based imaging strategy (Bakhsheshian et al., 2013b).”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Bakhsheshian, J., Wei, B.-R., Chang, K.-E., Shukla, S., Ambudkar, S. V., Simpson, R. M., Gottesman, M. M., & Hall, M. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-12-02
- Volume
- 110
- Issue
- 51
- Pages
- 20801-20806
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2057143539
- Cited by
- 48
- References
- 4
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2. https://app.cochat.ai/papers/10.1073/pnas.1312159110
- The paper
- Bakhsheshian, J., Wei, B.-R., Chang, K.-E., Shukla, S., Ambudkar, S. V., Simpson, R. M., Gottesman, M. M., & Hall, M. D. (2013). Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1312159110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.